Medical Oncology

, Volume 11, Issue 3–4, pp 127–132 | Cite as

Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation

  • A. Nagler
  • H. Elishoov
  • Y. Kapelushnik
  • R. Breuer
  • R. Or
  • D. Engelhard
Original Article

Abstract

CMV pneumonia is a frequent complication of allogeneic bone marrow transplantation (BMT). It usually appears 23 months following transplantation and is associated with a high mortality rate. The incidence of CMV pneumonia in our T-lymphocyte depleted allogeneic BMT recipients, transplanted between 1987–1991, was 18 out of 197 (9.2%) patients. In 3 patients (1.5% of allogeneic BMT recipients), pneumonia occurred prior to marrow engraftment, on days 12–16 post BMT. These patients did not develop acute GVHD in contrast to 9/11 patients who had acute GVHD in addition to developing CMV pneumonia between engraftment and day +100 (p<0.03). Furthermore, these three patients did not receive steroid therapy as opposed to 14/15 patients who were treated with steroids and eventually contracted CMV pneumonia post-engraftment (p<0.01). The three patients did not have two additional risk factors known for the development of CMV pneumonia: increasing age and a diagnosis of acute myeloblastic leukemia (AML) as the primary disease. Despite prompt diagnosis and therapy with ganciclovir and high doses of intravenous immunoglobulin (IVIG), two of the patients died. Tcell depleted BMT may be a risk factor for development of CMV pneumonia occurring prior to engraftment. In the era of post-BMT anti CMV prophylaxis, one should be aware that life-threatening CMV pneumonia may appear prior to engraftment and consider aggressive CMV prophylaxis.

Key Words

CMV disease pneumonia ganciclovir foscarnet intravenous immune globulin bone marrow transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after bone marrow transplantation.J lnfect Dis,153, 478–482 (1986).Google Scholar
  2. 2.
    Engelhard D, Or R, Strauss N etal. Cytomegalovirus infection and disease after Tcell depleted allogeneic bone marrow transplantation for malignant hematological diseases.Transplant Proc,21, 3101–3102 (1989).PubMedGoogle Scholar
  3. 3.
    Engelhard D, Marks MI, Good RA. Infection in bone marrow transplant recipients.J Pediat,108, 335–346 (1986).PubMedCrossRefGoogle Scholar
  4. 4.
    Sullivan KM, Meyers JD, FIournoy N, Storb R, Thomas ED: Early and [ate interstitial pneumonia following human bone marrow transplantation.Int J Cell Clon,4, 107–112 (1986).CrossRefGoogle Scholar
  5. 5.
    Guyotat O, Gibert R, Chomel J etal. Incidence and prognosis of cytomegalovirus infections following allogeneic bone marrow transplantation.J Med Virol,23, 393–399 (1987).PubMedCrossRefGoogle Scholar
  6. 6.
    Ljungman P, Engelhard D, Link Het al. Cytomegalovirus interstitial pneumonitis: treatment with ganciclovir and intravenous immune globulin. European Bone Marrow Transplant Group Experience.Clin Infect Diseases,14, 831–835 (1992).Google Scholar
  7. 7.
    Meyers JD, Reed E, Shepp Det al. Acyclovir for prevention of CMV infection and disease after allogeneic marrow transplantation.N Engl Med,318, 70–75 (1988).Google Scholar
  8. 8.
    Atkinson K, Downs K, Golenia M etal. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection.Brit J Haematol,79, 57–62 (1991).CrossRefGoogle Scholar
  9. 9.
    Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant.Ann Intern Med,118, 173–178 (1993).PubMedGoogle Scholar
  10. 10.
    Reusser P, Gambertoglio J, Lilleby K, Meyers JD. Phase III trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients.J Infect Dis,166. 473–479 (1992).PubMedGoogle Scholar
  11. 11.
    Goodrich JM, Mori M, Gleaves CAet al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.N Engl J Med,325, 1601–1607 (1991).PubMedGoogle Scholar
  12. 12.
    Schmidt GM, Horak.DA, Niland JC, Duncan SR, Forman SJ, Zaia JA.. A randomised, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants.N Eng J Med,324, 1005–11 (1991).CrossRefGoogle Scholar
  13. 13.
    Milpied N, Harousseau JL, Moreau P, Lacroix F, Ramee JF, Billaudel S. DHPG at CMV viremia after allogeneic bone marrow transplantation. Result over a four year period (1986-1990).Bone Marrow Transplant,7 (Suppl 2), 46 (1991).PubMedGoogle Scholar
  14. 14.
    Ljungman P, de Bock R, Cordonnier Cet al. Practices for cytomega!ovirus diagnosis, prophylaxis, and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases within the EBMT. Bone Marrow Transplantation.Bone Marrow Transplant,12, 399–403 (1993).PubMedGoogle Scholar
  15. 15.
    Waldmann H, Polliack A, Hale Get al. Elimination of graft versus host disease byin vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH).Lancet ii, 483485 (1984).Google Scholar
  16. 16.
    Engelhard D, Morag A, Naparstek Eet al. Prevention of herpes simplex virus infection in recipients of HLA-matched T-lymphocyte depleted bone marrow allografts.Is J Med Sci,24 (3), 145–150 (1988).Google Scholar
  17. 17.
    Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells.N Engl J Med,320, 1731- 1735 (1989).PubMedGoogle Scholar
  18. 18.
    Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.Blood,78, 1373–1380 (1991).PubMedGoogle Scholar
  19. 19.
    Reddehase MJ, Weiland F, Munch K, Jonjic S, Luske A, Koszinowski, UH. Interstitial routine cytomegalovirus pneumonia after irradiation: Characterisation of cells that limit viral replication during established infections of the lungs.J Virol,55, 264–273 (1985).PubMedGoogle Scholar
  20. 20.
    Riddell SR Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of clones.Science,257, 238–241 (1992).PubMedCrossRefGoogle Scholar
  21. 21.
    Henter JI, Elinder G, Ost A. FHL Study Group of the Histocyte Society. Diagnostic guidelines for hemophagocytic lymphohistiocytosis.Semin Oncol,18, 29–33. (1991)PubMedGoogle Scholar
  22. 22.
    Emanuel D, Cunningham I, JulesElysee Ket al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high dose intravenous immune globulin.Ann Intern Med,109, 777–782 (1988).PubMedGoogle Scholar
  23. 23.
    Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants.Ann Intern Med,109, 783–788 (1988).PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1994

Authors and Affiliations

  • A. Nagler
    • 1
  • H. Elishoov
    • 2
  • Y. Kapelushnik
    • 1
  • R. Breuer
    • 3
  • R. Or
    • 1
  • D. Engelhard
    • 2
  1. 1.Departments of Bone Marrow TransplantationHadassah University HospitalJerusalemIsrael
  2. 2.Departments of PediatricsHadassah University HospitalJerusalemIsrael
  3. 3.Departments of PulmonologyHadassah University HospitalJerusalemIsrael

Personalised recommendations